Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2001-05-31
2004-01-27
Eyler, Yvonne (Department: 1646)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S069100, C435S320100, C435S325000, C435S006120
Reexamination Certificate
active
06683169
ABSTRACT:
FIELD OF INVENTION
This invention relates to the fields of molecular biology and peptide transporters. Specifically, nucleic and amino acid sequences for expressing the human peptide histidine transporter 1, (hPHT1) and fragments thereof as well as hPHT1 immunospecific antibodies are provided. Methods and kits employing the compositions of the invention are also disclosed.
BACKGROUND OF THE INVENTION
Several publications are referenced in this application in order to more fully describe the state of the art to which this invention pertains. The disclosure of each of these publications is incorporated by reference herein.
Peptide transport is a specific biochemical process in which small peptides are transported across a membrane by energy-dependent saturable carriers. While the existence of a transport process for intact peptides in the brush border membrane of intestinal and renal absorptive epithelial cells has been known for almost three decades, it is only recently that the molecular nature of the proteins responsible for the transport process has been elucidated. Two peptide transporters, PEPT 1 and PEPT 2, have been cloned. The cloned transporters catalyze active transport of intact di- and tripeptides and utilize a transmembrane electrochemical H+ gradient as the driving force. The characteristic of H+ coupling makes PEPT 1 and PEPT 2 unique among the transporters thus far identified in mammalian cells. In addition, the peptide transporters have immediate pharmacologic relevance because a number of peptide-like drugs are recognized as substrates by these transporters. Recently, cultured cell lines of intestinal and renal origin that express PEPT 1 and PEPT 2 have been identified. (Oh et al., 1999, Pharm Biotechnol. 12:59-88; Liang et al., 1995, J Biol Chem. 270:6456-6463; Fei et al., 1994, Nature 368:563-566; Dantzig et el., 1994, Science 264:430-433).
PepT1 belongs to the proton oligopeptide transporter (POT) superfamily, in which all of the known peptide transporters, with the exception of HPT1 (a cadherin family member), are grouped (Meredith and Boyd, 2000, Cell Mol Life Sci. 57:754-778; Graul and Sadee, 1997, Pharm. Res. 14(4):388-400). Of these transporters, PepT1 has been extensively characterized and appears to be the predominant peptide transporter in the gastrointestinal tract (GIT) (Pauletti et al., 1996, J Cont Rel. 41:3-17; Oh et al., 1999, Pharm Biotechnol. 12:59-88; Ganapathy et al., 1998, Biochem Biophys Res Commun. 246:470-475; Tamai et al., 1997, J Pharm Pharmacol. 49:796-801). More recently, HPT-1 has been identified in Caco-2 cells (Dantzig et el., 1994, Science 264:430-433; Hu et al., 1994, Pharm Res. 11:1405-1413; Hu et al. 1995, Pharm Res. 12:1120-1125; Snyder et al., 1997, Antimicrob Agents Chemother; Yang, 1998, thesis, Purdue University, West Lafayette, Ind.).
Inasmuch as the therapeutic use of peptide-based pharmaceuticals is a burgeoning area in rational drug design, elucidation of the specificity and molecular function of different transporter molecules is highly desirable for the treatment of a variety of pathological disorders.
SUMMARY OF THE INVENTION
The present invention relates to the identification of novel nucleic acid molecules and proteins encoded by such nucleic acid molecules or variants thereof, that participate in peptide transport within the GIT.
According to one aspect of the invention, an isolated nucleic acid molecule is provided which includes a complete coding region for a human peptide histidine transporter 1 (hPHT1)protein of a predicted size between about 50 and 80 kilodaltons. The hPHT1 protein is preferably about 65 kilodaltons. As predicted by structural analysis, the hPHT1 protein comprises twelve putative transmembrane domains (TM) and includes NH
2
— and COOH terminal ends that are localized to the cytoplasm of cells.
In yet another embodiment of the invention, an isolated nucleic acid encoding a hPHT1 protein is provided. In a particularly preferred embodiment, the hPHT1 protein has an amino acid sequence the same as Sequence I.D. No. 2. An exemplary hPHT1 encoding nucleic acid molecule of the invention comprises Sequence I.D. No. 1.
In another embodiment of the invention, an isolated nucleic acid encoding a splice variant of hPHT1 protein is provided. In a particularly preferred embodiment, a splice variant of hPHT protein has an amino acid sequence the same as Sequence I.D. No. 4. An exemplary hPHT1 splice variant encoding nucleic acid molecule of the invention comprises Sequence I.D. No. 3.
In yet another embodiment of the invention, variant hPHT1 encoding nucleic acids have been isolated. These nucleic acid sequences are referred to herein as SEQ ID NOs: 53 and 55. The amino acid sequences encoded by SEQ ID Nos: 53 and 55 are referred to herein as SEQ ID NOs: 54 and 56.
According to another aspect of the invention, antibodies immunologically specific for the proteins described hereinabove are provided.
In addition, this invention presents methods for screening potentially beneficial therapeutic agents which modulate hPHT1 meditated transport. Agents so identified are also within the scope of the present invention.
REFERENCES:
patent: 5965456 (1999-10-01), Malmqvist et al.
patent: 6057098 (2000-05-01), Buechler et al.
Doerks et al. Protein annotation: detective work for function prediction. Trends in Genetics. Jun. 1998, vol. 14, No. 6, pp. 248-250.*
Brenner et al. Errors in Genome Annotation. Trends in Genetics 1999, 15:132-133.*
Bork et al. Go Hunting in sequence databases but watch out for the traps. Trends in Genetics 1996, 12:425-427.*
Voet et al.. Biochemistry. 1990. John Wiley & Sons, Inc. pp. 126-128 and 228-234.*
Kaufman, R.J., “High Level Production of Proteins in Mammalian Cells”; Genetic Engineering Principles and Methods, ed. J. K. Setlow, Plenum Press 9:155-198 (1988).
Island, M.D., et al., “Isolation and characterization ofS. cerevisiaemutants deficient in amino acid-inducible peptide transport”; Curr. Genet., 20:457-463 (1991).
Marder, R., et al., “Isolation of a Peptide Transport-Deficient Mutant of Yeast”; J. Bacteriol., 136:1174-1177 (1978).
Bradner, W.T., et al., “Screening Systems”; Antineoplastic Agents, eds. W. A. Remers, John Wiley and Sons, Inc. N.Y. (1984).
Hodgson, J., “Data-Directed Drug Design”; Bio/Technology 9:19-21 (1991).
Wells, J.A., “Systematic Mutational Analyses of Protein-Protein Interfaces”; Meth. Enzym., 202:390-411(1991).
Wang, J., et al., “Functional and Molecular Characteristics of Na(+)-dependent Nucleoside Transporters”; Pharm Res., 14:1524-1532 (1997).
Baskaran, N., et al., “Uniform amplification of a mixture of deoxyribonucleic acids with varying GC content”; Genome Res, 6:633-638 (1996).
Botka, C.W., et al., “Human proton/oligopeptide transporter (POT) genes: Identification of putative human genes using bioinformatics”; AAPS PharmSci, 2:1-22 (2000).
“Epitope Tagging”; Antibodies as Tools in Cell Biology, eds. David L. Spector, et al., Cold Spring Harbor Laboratory Press, Woodbury, NY, 1:71.1-71.6 (1998).
Choi, J-S, et al., “Improved Cycle sequencing of GC-rich DNA template”; Exp Mol Med, 31:20-24 (1999).
Chomczynski, P., et al., “Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction”; Anal. Biochem., 162:156-159 (1987).
Covitz, K-M, et al., “Membrane topology of the human dipeptide transporter, hPEPT1, determined by epitope insertions”; Biochemistry, 37:15214-15221 (1998).
Dantzig A.H., et al., “Association of intestinal peptide transport with a protein related to the cadherin superfamily”; Science, 264:430-433 (1994).
De Felice, M., et al., “Escherichia coliK-12 mutants altered in the transport systems for oligo- and dipeptides”; J. Bacteriol., 116:751-756 (1973).
Dudley, A.J., et al., “The organic cation transporter OCT2 mediates the uptake of beta-adrenoceptor antagonists across the apical membrane of renal LLC-PK(1) cell monolayers”; Br J Pharmacol, 131:71-79 (2000).
Erickson, R.H., et al., “Regional expression and dietary regulation of rat small intestinal peptide and amino acid transporter mRNAs”
Herrera-Ruiz Dea
Knipp Gregory T.
Dann Dorfman Herrell & Skillman P.C.
Eyler Yvonne
Murphy Joseph F.
Rutgers The State University of New Jersey
LandOfFree
Nucleic acid encoding the human peptide histidine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleic acid encoding the human peptide histidine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acid encoding the human peptide histidine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3189985